Firebrick Pharma Ltd - Asset Resilience Ratio
Firebrick Pharma Ltd (FRE) has an Asset Resilience Ratio of 0.29% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Firebrick Pharma Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2021)
This chart shows how Firebrick Pharma Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Firebrick Pharma Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Firebrick Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Firebrick Pharma Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$5.35K | 0.29% |
| Total Liquid Assets | AU$5.35K | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Firebrick Pharma Ltd maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Firebrick Pharma Ltd Industry Peers by Asset Resilience Ratio
Compare Firebrick Pharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Roche Holding AG
SW:ROP |
Drug Manufacturers - General | 9.82% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281 |
Drug Manufacturers - General | 6.44% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for Firebrick Pharma Ltd (2021–2021)
The table below shows the annual Asset Resilience Ratio data for Firebrick Pharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 2.41% | AU$283.24K ≈ $200.41K |
AU$11.77 Million ≈ $8.33 Million |
-- |
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.